Loading…
Telix Pharmaceuticals Limited is projected to rise to $14.89 by 2027, a +34% move from its current price of $11.14. TLX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $10.86 | $11.15 | $11.44 | +0.06% |
| Jul 14 | $10.75 | $11.15 | $11.57 | +0.13% |
| Jul 15 | $10.67 | $11.16 | $11.68 | +0.19% |
| Jul 16 | $10.60 | $11.17 | $11.77 | +0.25% |
| Jul 17 | $10.54 | $11.17 | $11.85 | +0.31% |
| Jul 18 | $10.49 | $11.18 | $11.92 | +0.38% |
| Jul 19 | $10.44 | $11.19 | $11.99 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.44 | $11.19 | $11.99 | +0.44% |
| Week 2 | $10.19 | $11.24 | $12.39 | +0.88% |
| Week 3 | $10.01 | $11.29 | $12.72 | +1.32% |
| Week 4 | $9.87 | $11.34 | $13.02 | +1.77% |
| Week 5 | $9.76 | $11.39 | $13.29 | +2.22% |
| Week 6 | $9.66 | $11.44 | $13.55 | +2.67% |
| Week 7 | $9.57 | $11.49 | $13.79 | +3.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. It operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic TLX591 is a lutetium-labeled radiopharmaceutical conjugate in Phase 3 clinical trials for advanced prostate cancer, and the company is advancing a broad portfolio including TLX250 for advanced metastatic kidney cancer, TLX101 for glioblastoma, TLX66 for bone marrow conditioning, and Illuccix and Gozellix for prostate cancer, among other programs.
Telix operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally, with a strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Telix Pharmaceuticals Limited (TLX) is a healthcare company focused on radiopharmaceuticals and related imaging and therapeutic products. The stock trades at $11.14 and has a market capitalization of $3.77B, with a rank of 1581. The current price and market position are complemented by a defined price trajectory in the forecast, which shows a shift from neutral in 2026 to bullish thereafter.
The 30-day technical picture and nearby support/resistance levels provide a framework for near-term action, while the multi-year forecast points to substantial upside in the decades ahead.
A major floor 38.3% below — a decisive break under it would weaken the trend.
The nearest floor, 21.3% below — buyers have tended to step in here.
The nearest ceiling, 9.1% above — a clean break opens room to run.
A major ceiling 26.3% above — clearing it would confirm fresh momentum.
Key TLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.67 | Sell | $11.52 | Sell |
| MA 10 | $11.56 | Sell | $11.39 | Sell |
| MA 20 | $10.78 | Buy | $10.99 | Buy |
| MA 50 | $10.38 | Buy | $10.40 | Buy |
| MA 100 | $9.55 | Buy | $9.95 | Buy |
| MA 200 | $9.27 | Buy | $10.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.92 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 29.51 | Neutral |
| Williams %R (14) | -46.98 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 9.11 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 53.02 | Neutral |
| TRIX (15) | 0.60 | Buy |
| Awesome (5,34) | 1.44 | Buy |
| Ultimate (7,14,28) | 50.03 | Neutral |
| Momentum (10) | 0.28 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 11.54 | Sell |
| ADX (14) | 26.75 | Buy |
| ATR (14) | 0.27 | Info |
The sentiment is BULLISH with the RSI16 at 50. The stock is trading above both the 50-day and 200-day moving averages, with the SMA50 at $10.38 and the SMA200 at $9.27. Support is at $8.77 and resistance at $12.15, implying a defined trading range around the current level.
Over the last 30 days, the range has spanned from a low of $9.38 to a high of $13.23, highlighting potential for continued volatility within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.41 | $11.14 | $16.01 | 0% | Neutral | |
| $11.91 | $14.89 | $19.68 | +34% | Bullish | |
| $12.97 | $16.67 | $22.82 | +50% | Bullish | |
| $14.10 | $18.52 | $26.07 | +66% | Bullish | |
| $16.82 | $22.52 | $32.46 | +102% | Bullish | |
| $20.40 | $27.81 | $40.91 | +150% | Bullish | |
| $23.78 | $32.94 | $49.36 | +196% | Bullish | |
| $26.74 | $37.62 | $57.32 | +238% | Bullish | |
| $27.51 | $39.26 | $60.75 | +252% | Bullish | |
| $29.74 | $43.05 | $67.56 | +286% | Bullish | |
| $45.70 | $70.46 | $117.41 | +533% | Bullish | |
| $101.99 | $175.22 | $318.59 | +14.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $6.41 | $11.14 | $13.18 | +0.00% |
| August 2026 | $9.67 | $11.40 | $13.79 | +2.36% |
| September 2026 | $9.94 | $11.79 | $14.42 | +3.44% |
| October 2026 | $9.93 | $11.85 | $14.62 | +0.49% |
| November 2026 | $10.11 | $12.13 | $15.07 | +2.31% |
| December 2026 | $10.62 | $12.79 | $16.01 | +5.51% |
Click any year to see its month-by-month TLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TLX is projected to trade between $6.41 and $16.01, averaging $11.14 — a potential gain of 0% from today's $11.14. A consolidation phase looks the most probable path here.
Telix Pharmaceuticals Limited's 2027 outlook centres on $14.89, within a $11.91 to $19.68 range. That is up +34% on the projected 2026 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2028, TLX could reach as high as $22.82, with a base case around $16.67 and support toward $12.97 — roughly +50% from $11.14. Buyers look set to stay in control over this stretch.
Expect TLX to range from $14.10 to $26.07 through 2029. The $18.52 average target implies a +66% move from current prices. That is up +11% on the projected 2028 average. Momentum favours further upside here.
The TLX price prediction for 2030 points to an average of $22.52 (low $16.82, high $32.46) — a potential gain of +102% on today's $11.14. Buyers look set to stay in control over this stretch.
In 2031, TLX is projected to trade between $20.40 and $40.91, averaging $27.81 — a potential gain of +150% from today's $11.14. That is up +23% on the projected 2030 average. Momentum favours further upside here.
Telix Pharmaceuticals Limited's 2032 outlook centres on $32.94, within a $23.78 to $49.36 range. That is up +18% on the projected 2031 average. That marks a +196% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TLX could reach as high as $57.32, with a base case around $37.62 and support toward $26.74 — roughly +238% from $11.14. Momentum favours further upside here.
Expect TLX to range from $27.51 to $60.75 through 2034. The $39.26 average target implies a +252% move from current prices. That is up +4% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TLX price prediction for 2035 points to an average of $43.05 (low $29.74, high $67.56) — a potential gain of +286% on today's $11.14. Momentum favours further upside here.
In 2040, TLX is projected to trade between $45.70 and $117.41, averaging $70.46 — a potential gain of +533% from today's $11.14. That is up +64% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Telix Pharmaceuticals Limited's 2050 outlook centres on $175.22, within a $101.99 to $318.59 range. That is up +149% on the projected 2040 average. That marks a +14.7x change versus current levels. Momentum favours further upside here.
Investing $1,000 in TLX today (≈ 89.766607 TLX) could be worth
$15,729.35
+$14,729.35 (+1473%) by 2050 · US Dollar
Based on the average projected TLX price of $175.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TLXwould be worth at today's price.
$1,000 invested in TLX on Jul 10, 2025 (≈ 62.1118 TLX) would be worth
$691.93
-$308.07 (-30.8%) today · 0.69× · US Dollar
Based on a TLX entry price of $16.1 vs. today's $11.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.87 | $938.5 | -6.1% |
| 1 month ago | $9.44 | $1,180.08 | +18.0% |
| 3 months ago | $10.54 | $1,056.93 | +5.7% |
| 6 months ago | $7.55 | $1,475.5 | +47.5% |
| 1 year ago | $16.1 | $691.93 | -30.8% |
| All time (1.7y) ago | $15.15 | $735.31 | -26.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TLX forecast.
Our base-case forecast reaches $22.00 around 2030.
Implied market cap at $22.00: $7.45B
The year-by-year forecast shows a clear long-run upside, with 2026 averaging $11.14 but a path turning bullish from 2027 onward. By 2030 the average forecast is $22.51 with a 102% ROI and a bullish sentiment, while 2040 projects an average of $70.49 with a 532.7% ROI and continued bullishness. By 2050 the average climbs to $175.39 with a 1474.4% ROI and bullish sentiment, underscoring substantial potential over the extended horizon.
These estimates, not guarantees, reflect the projected price path and should be considered alongside inherent market risk.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $22.51, with a minimum of $16.81 and a maximum of $32.44, and a 102% ROI; sentiment is bullish.
The forecast shows a shift from neutral in 2026 (average $11.14) to bullish from 2027 onward, with rising averages and higher ROIs through 2030, 2040, and 2050.
Yes. The forecast maximums rise to $32.44 by 2030, $117.44 by 2040, and $318.90 by 2050, indicating that surpassing $100 could occur in the longer term (by 2040 or later) per the projected max values.
TLX is priced at $11.14 with a market capitalization of $3.77B and a rank of 1581.
The 2050 forecast shows an average of $175.39, a minimum of $102.08, a maximum of $318.90, and a 1474.4% ROI, with bullish sentiment.
Telix Pharmaceuticals Limited Community Discussion
0Share your Telix Pharmaceuticals Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.